DBV Technologies (NASDAQ:DBVT) Stock Price Up 11.2% – What’s Next?

DBV Technologies S.A. (NASDAQ:DBVT)’s share price rose 11.2% on Tuesday. The stock traded as high as $9.93 and last traded at $10.0630. 32,827 shares were traded during mid-day trading, a decline of 90% from the average session volume of 318,724 shares. The stock had previously closed at $9.05.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating on shares of DBV Technologies in a research report on Friday. Citigroup restated a “market outperform” rating on shares of DBV Technologies in a report on Thursday, October 29th. Guggenheim dropped their price target on shares of DBV Technologies from $51.00 to $46.00 and set a “buy” rating on the stock in a research note on Friday. Citizens Jmp cut their price objective on DBV Technologies from $55.00 to $47.00 and set a “market outperform” rating for the company in a report on Thursday, October 29th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of DBV Technologies in a research report on Thursday, October 15th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.25.

DBV Technologies Trading Up 10.7%

The business’s fifty day moving average price is $11.42 and its two-hundred day moving average price is $16.89. The firm has a market cap of $630.06 million, a P/E ratio of -3.32 and a beta of -1.04.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Wednesday, October 28th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.41). DBV Technologies had a negative return on equity of 115.81% and a negative net margin of 5,392.17%. The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $0.56 million. Research analysts predict that DBV Technologies S.A. will post -2.22 EPS for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

Several hedge funds and other institutional investors have recently modified their holdings of DBVT. Vivo Capital LLC raised its position in shares of DBV Technologies by 8.4% during the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after buying an additional 205,943 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in DBV Technologies in the 1st quarter valued at approximately $21,159,000. Perceptive Advisors LLC bought a new stake in shares of DBV Technologies in the 1st quarter worth approximately $20,146,000. Atika Capital Management LLC grew its holdings in shares of DBV Technologies by 31.1% during the 1st quarter. Atika Capital Management LLC now owns 271,300 shares of the company’s stock worth $5,667,000 after purchasing an additional 64,419 shares in the last quarter. Finally, Elmind Capital LP acquired a new stake in shares of DBV Technologies during the 1st quarter worth approximately $5,536,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies’ lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.